{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:09:50Z","timestamp":1789056590864,"version":"build-2803163510"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016616","name":"Cystic Fibrosis Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016616","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.rmed.2026.109063","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:44:30Z","timestamp":1785512670000},"page":"109063","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-world efficacy, safety and heterogenicity of efficacy of elexacaftor-tezacaftor-ivacaftor in younger children (6-11 years old) with cystic fibrosis"],"prefix":"10.1016","volume":"262","author":[{"given":"Shahid","family":"Sheikh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6828-0278","authenticated-orcid":false,"given":"Melissa","family":"Holtzlander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4703-4342","authenticated-orcid":false,"given":"Mariah","family":"Eisner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Gelpi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Mull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0674-8568","authenticated-orcid":false,"given":"Sehyr","family":"Imran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavitha","family":"Kotha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen S.","family":"McCoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.rmed.2026.109063_bib1","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jcf.2014.09.005","article-title":"Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation","volume":"13","author":"De Boeck","year":"2014","journal-title":"J. Cyst. Fibros."},{"issue":"3","key":"10.1016\/j.rmed.2026.109063_bib2","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.rmed.2026.109063_bib3","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.rmed.2026.109063_bib4","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of Elexacaftor\/Tezacaftor\/Ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2026.109063_bib5","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1164\/rccm.201608-1754OC","article-title":"VX13-809-011 Part B Investigator Group. Lumacaftor\/ivacaftor in patients aged 6\u201311 years with cystic fibrosis and homozygous for F508del-CFTR","volume":"195","author":"Milla","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"19","key":"10.1016\/j.rmed.2026.109063_bib6","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"VX17-445-102 study group. Elexacaftor-Tezacaftor-Ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.rmed.2026.109063_bib7","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1001\/jamaoto.2023.2701","article-title":"Elexacaftor-Tezacaftor-Ivacaftor therapy for chronic sinus disease in cystic fibrosis","volume":"149","author":"Sheikh","year":"2023","journal-title":"JAMA Otolaryngol. Head Neck Surg."},{"issue":"4","key":"10.1016\/j.rmed.2026.109063_bib8","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jcf.2022.12.012","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy in children with cystic fibrosis - a comprehensive assessment using lung clearance index, spirometry, and functional and structural lung MRI","volume":"22","author":"Streibel","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.rmed.2026.109063_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2025.102345","article-title":"Real-life impact of genotype and severity of lung disease on efficacy of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis","volume":"88","author":"Sheikh","year":"2025","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.rmed.2026.109063_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2025.108274","article-title":"Real -world impact of previous exposure to CFTR modulators on clinical parameters and chronic sinus disease in people with cystic fibrosis on elexacaftor-tezacaftor-ivacaftor","volume":"247","author":"Holtzlander","year":"2025","journal-title":"Respir. Med."},{"issue":"8","key":"10.1016\/j.rmed.2026.109063_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.71236","article-title":"A new simple to use chest CT scoring system: validation study","volume":"60","author":"Sheikh","year":"2025","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.rmed.2026.109063_bib12","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2026.109063_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1176815","article-title":"Real-life impact of highly effective CFTR modulator therapy in children with cystic fibrosis","volume":"14","author":"Olivier","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"11","key":"10.1016\/j.rmed.2026.109063_bib14","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1002\/ppul.27125","article-title":"Effectiveness and safety of elexacaftor\/tezacaftor\/ivacaftor treatment in children aged 6-11 years with cystic fibrosis in a real-world setting","volume":"59","author":"Dacco","year":"2024","journal-title":"Pediatr. Pulmonol."},{"issue":"1","key":"10.1016\/j.rmed.2026.109063_bib15","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02435-2024","article-title":"Elexacaftor\/tezacaftor\/ivacaftor in children aged \u22656 years with cystic fibrosis heterozygous for F508del and a minimal function mutation: results from a 96-week open-label extension study","volume":"66","author":"Mall","year":"2025","journal-title":"Eur. Respir. J."},{"issue":"9","key":"10.1016\/j.rmed.2026.109063_bib16","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1002\/ppul.25980","article-title":"Elexacaftor\/tezacaftor\/ivacaftor in children aged 6-11 years with cystic fibrosis, at least one F508DEL allele, and advanced lung disease: a 24-week observational study","volume":"57","author":"Salvatore","year":"2022","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.rmed.2026.109063_bib20","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/M13-0636","article-title":"Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation patient registry","volume":"161","author":"MacKenzie","year":"2014","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.rmed.2026.109063_bib21","doi-asserted-by":"crossref","first-page":"5242","DOI":"10.1128\/MCB.25.12.5242-5252.2005","article-title":"Most F508del-CFTR is targeted to degradation at an early folding checkpoint and independently of calnexin","volume":"25","author":"Farinha","year":"2005","journal-title":"Mol. Cell Biol."},{"issue":"11","key":"10.1016\/j.rmed.2026.109063_bib17","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1513\/AnnalsATS.202501-103OC","article-title":"Clinical effectiveness of Elexacaftor\/Tezacaftor\/Ivacaftor in 6- to 11-Year-Olds with cystic fibrosis: an observational study","volume":"22","author":"Pittman","year":"2025","journal-title":"Ann. Am. Thorac. Soc."},{"issue":"6","key":"10.1016\/j.rmed.2026.109063_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.71166","article-title":"Real-world improvements of lung clearance index and ventilation distribution efficiency in children with cystic fibrosis after Elexacaftor\/Tezacaftor\/Ivacaftor initiation","volume":"60","author":"Henriksen","year":"2025","journal-title":"Pediatr. Pulmonol."},{"issue":"4","key":"10.1016\/j.rmed.2026.109063_bib19","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S2213-2600(22)00434-9","article-title":"Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"Lancet Respir. Med."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611126004312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611126004312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:42:38Z","timestamp":1789054958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611126004312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":21,"alternative-id":["S0954611126004312"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2026.109063","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world efficacy, safety and heterogenicity of efficacy of elexacaftor-tezacaftor-ivacaftor in younger children (6-11 years old) with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2026.109063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109063"}}